Pharmacogenetics of osteoporosis and the prospect of individualized prognosis and individualized therapy

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 15, Issue 6, 2008, Pages 481-488

  Nguyen, Tuan V ^a   Center, Jacqueline R ^a   Eisman, John A ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Genome wide association; Linkage; Osteonecrosis of the jaw; Osteoporosis; Pharmacogenetics

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; ANDROGEN RECEPTOR; APOLIPOPROTEIN E; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN RECEPTOR; CALCIUM SENSING RECEPTOR; CARBOXY TERMINAL TELOPEPTIDE; CELL MARKER; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA1; DEOXYPYRIDINOLINE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HYDROXYPROLINE; INTERLEUKIN 6; METALLOPROTEINASE; METALLOPROTEINASE 1; OSTEOCALCIN; PARATHYROID HORMONE RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PYRIDINOLINE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

BONE DENSITY; BONE NECROSIS; BONE STRENGTH; BONE TURNOVER; CHROMOSOME ANALYSIS; FRAGILITY FRACTURE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; INDIVIDUALIZATION; JAW DISEASE; OSTEOPOROSIS; PHARMACOGENETICS; PHENOTYPE; PROGNOSIS; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

BONE DENSITY CONSERVATION AGENTS; COLLAGEN; FRACTURES, BONE; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; OSTEOPOROSIS; PEPTIDE FRAGMENTS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CALCITRIOL;

EID: 56749161536     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32831a46be     Document Type: Review

References (66)

1. Anonymous. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785-795.
2. Nguyen ND, Eisman JA, Center JR, et al. Risk factors for fracture in non-osteoporotic men and women. J Clin Endocrinol Metab 2007; 92:955-962.
3. Riggs BL, Melton LJ 3rd. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002; 17:11-14.
4. Delmas PD, Li Z, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 2004; 19:330-337.
5. Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 2005; 26:97-122.
6. Seibel MJ, Naganathan V, Barton I, et al. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 2004; 19:323-329.
7. Meier C, Nguyen TV, Center JR, et al. Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study. J Bone Miner Res 2005; 20:579-587.
8. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996; 11:1531-1538.
9. Tokita A, Kelly PJ, Nguyen TV, et al. Genetic influences on type I collagen synthesis and degradation: further evidence for genetic regulation of bone turnover. J Clin Endocrinol Metab 1994; 78:1461-1466.
10. Harris M, Nguyen TV, Howard GM, et al. Genetic and environmental correlations between bone formation and bone mineral density: a twin study. Bone 1998; 22:141-145.
11. Nguyen TV, Howard GM, Kelly PJ, et al. Bone mass, lean mass, and fat mass: same genes or same environments? Am J Epidemiol 1998; 147:3-16.
12. Nguyen TV, Eisman JA. Genetics of fracture: challenges and opportunities. J Bone Miner Res 2000; 15:1253-1256.
13. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332:767-773.
14. Deng HW, Chen WM, Recker S, et al. Genetic determination of Colles' fracture and differential bone mass in women with and without Colles' fracture. J Bone Miner Res 2000; 15:1243-1252.
15. Michaelsson K, Melhus H, Ferm H, et al. Genetic liability to fractures in the elderly. Arch Intern Med 2005; 165:1825-1830.
16. Makovey J, Nguyen TV, Naganathan V, et al. Genetic effects on bone loss in peri- and postmenopausal women: a longitudinal twin study. J Bone Miner Res 2007; 22:1773-1780.
17. Howard GM, Nguyen TV, Harris M, et al. Genetic and environmental contributions to the association between quantitative ultrasound and bone mineral density measurements: a twin study. J Bone Miner Res 1998; 13:1318-1327.
18. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273:1516-1517.
19. Nguyen TV, Blangero J, Eisman JA. Genetic epidemiological approaches to the search for osteoporosis genes. J Bone Miner Res 2000; 15:392-401.
20. Lander ES, Schork NJ. Genetic dissection of complex traits. Science 1994; 265:2037-2048.
21. Schork NJ, Cardon LR, Xu X. The future of genetic epidemiology. Trends Genet 1998; 14:266-272.
22. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367:284-287.
23. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptor alleles: correction. Nature 1997; 387:106.
24. Eisman JA. Vitamin D receptor gene alleles and osteoporosis: an affirmative view. J Bone Miner Res 1995; 10:1289-1293.
25. Gong G, Stern HS, Cheng SC, et al. The association of bone mineral density with vitamin D receptor gene polymorphisms. Osteoporos Int 1999; 9:55-64.
26. Ralston SH, de Crombrugghe B. Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev 2006; 20:2492-2506.
27. Ralston SH, Uitterlinden AG, Brandi ML, et al. Large-scale evidence for the effect of the COLIA1 Sp1 polymorphism on osteoporosis outcomes: the GENOMOS study. PLoS Med 2006; 3:e90.
28. Nguyen TV, Esteban LM, White CP, et al. Contribution of the collagen I alpha1 and vitamin D receptor genes to the risk of hip fracture in elderly women. J Clin Endocrinol Metab 2005; 90:6575-6579.
29. Huang QY, Recker RR, Deng HW. Searching for osteoporosis genes in the postgenome era: progress and challenges. Osteoporos Int 2003; 14:701-715.
30. Nguyen TV. Pharmacogenetics of antiresorptive therapy efficacy: a Bayesian interpretation. Osteoporos Int 2005; 16:857-860.
31. Gong Y, Vikkula M, Boon L, et al. Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13. Am J Hum Genet 1996; 59:146-151.
32. Johnson ML, Gong G, Kimberling W, et al. Linkage of a gene causing high bone mass to human chromosome 11 (11q12-13). Am J Hum Genet 1997; 60:1326-1332.
33. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001; 107:513-523.
34. Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 2002; 70:11-19.
35. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002; 346:1513-1521.
36. Van Wesenbeeck L, Cleiren E, Gram J, et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 2003; 72:763-771.
37. Tran BN, Nguyen ND, Eisman JA, Nguyen TV. Association between LRP5 polymorphism and bone mineral density: a Bayesian meta-analysis. BMC Med Genet 2008; 9:55. A Bayesian meta-analysis based on summary data showed that the association between polymorphisms of the LRP5 gene and BMD was modest.
38. The International HapMap Project. Nature 2003; 426:789-96.
39. Wang WY, Barrett BJ, Clayton DG, et al. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 2005; 6:109-118.
40. Reich DE, Lander ES. On the allelic spectrum of human disease. Trends Genet 2001; 17:502-510.
41. Yang Q, Khoury MJ, Friedman J, et al. How many genes underlie the occurrence of common complex diseases in the population? Int J Epidemiol 2005; 34:1129-1137.
42. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med 2008; 358:2355-2365. A GWA study using 301 019 SNPs on Icelandic, Danish, and Australian participants. The authors discovered that in addition to regions close to or within the RANKL, OPG, and ESR1 genes, there are various SNPs that were associated with BMD and fracture risk.
43. van Meurs JB, Trikalinos TA, Ralston SH, et al. Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA 2008; 299:1277-1290. A meta-analysis of association between polymorphisms of the LRP5 gene and BMD and fracture risk. The authors conclude that there was an association between common LRP5 variants and BMD or fracture risk; however, the magnitude of the effect was modest.
44. Richards JB, Rivadeneira F, Inouye M, et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 2008; 371:1505-1512. A GWA study using 314075 SNPs on 2094 women in an initial sample and then validated in a second sample of 6463 individuals from three cohorts in Europe. The authors found two gene variants that were associated with the risk of osteoporosis and fracture.
45. Kiel DP, Demissie S, Dupuis J, et al. Genome-wide association with bone mass and geometry in the Framingham Heart Study. BMC Med Genet 2007; 8 (Suppl 1):S14. A GWA study using Affymetrix 100K SNP GeneChip marker set in the Framingham Heart Study. The authors identified 20 SNPs that were associated with BMD. These SNPs were independent from the SNPs identified by Styrkarsdottir et al [42••].
46. Delmas PD, Rizzoli R, Cooper C, et al. Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int 2005; 16:1-5.
47. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002; 359:2018-2026.
48. Francis RM. Nonresponse to osteoporosis treatment. J Br Menopause Soc 2004; 10:76-80.
49. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348:529-537.
50. Kalow W. Pharmacogenetics in biological perspective. Pharmacol Rev 1997; 49:369-379.
51. Vesell ES. Advances in pharmacogenetics and pharmacogenomics. J Clin Pharmacol 2000; 40:930-938.
52. Nakamura M, Zhang ZQ, Shan L, et al. Allelic variants of human calcitonin receptor in the Japanese population. Hum Genet 1997; 99:38-41.
53. Palomba S, Numis FG, Mossetti G, et al. Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with Beml vitamin D receptor genotypes. Clin Endocrinol (Oxf) 2003; 58:365-371.
54. Palomba S, Numis FG, Mossetti G, et al. Raloxifene administration in postmenopausal women with osteoporosis: effect of different Bsml vitamin D receptor genotypes. Hum Reprod 2003; 18:192-198.
55. Palomba S, Orio F Jr, Russo T, et al. Bsml vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos Int 2005; 16:943-952.
56. Qureshi AM, Herd RJ, Blake GM, et al. COLIA1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy. Calcif Tissue Int 2002; 70:158-163.
57. Meyer S, Haist M, Schaefer S, et al. Association of COLIA1 Sp1 polymorphism with the effect of subcutaneously injected recombinant hGH in GH-deficient adults. Pharmacogenomics 2008; 9:1017-1026. A study of association between COLIA1 Sp1 polymorphism and dose of subcutaneously injected recombinant hGH in 122 adults with growth hormone deficiency. Individuals with GG genotype required a higher dose of hGH than those with TT homozygotes.
58. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144:753-761.
59. Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 2006; 64:917-923.
60. Sarasquete ME, Garcia-Sanz R, Marin L, et al. Bisphosphonate- related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 2008; 112:2709-2712. The first genome-wide study suggested that four SNPs were associated with the risk of bisphosphonate-induced ONJ.
61. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005; 115:3318-3325.
62. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 2005; 20:1185-1194.
63. Nguyen ND, Pongchaiyakul C, Center JR, et al. Identification of high-risk individuals for hip fracture: a 14-year prospective study. J Bone Miner Res 2005; 20:1921-1928.
64. Leslie WD, Lix LM, Tsang JF, et al. Single-site vs multisite bone density measurement for fracture prediction. Arch Intern Med 2007; 167:1641-1647.
65. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35:375-382.
66. Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001; 166:63-67.